<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /opt/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Recommendations for defining treatment outcomes in major psychiatric disorders leveraging real-world data</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Elise</forename><surname>Koch</surname></persName>
							<email>e.m.koch@medisin.uio.no</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Precision Psychiatry</orgName>
								<orgName type="department" key="dep2">Division of Mental Health and Addiction</orgName>
								<orgName type="department" key="dep3">Institute of Clinical Medicine</orgName>
								<orgName type="institution" key="instit1">Oslo University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Sophie</forename><surname>Smart</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Division of Psychological Medicine and Clinical Neurosciences</orgName>
								<orgName type="laboratory">Centre for Neuropsychiatric Genetics and Genomics</orgName>
								<orgName type="institution">Cardiff University</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Guðmundur</forename><surname>Einarsson</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">deCODE Genetics</orgName>
								<address>
									<settlement>Reykjavik</settlement>
									<country key="IS">Iceland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD</roleName><forename type="first">Anders</forename><surname>Kämpe</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute for Molecular Medicine Finland (FIMM)</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Molecular Medicine and Surgery (MMK)</orgName>
								<address>
									<addrLine>Karolinska Institutet</addrLine>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Lina</forename><surname>Jonsson</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="department" key="dep2">Institute of Neuroscience and Physiology at the Sahlgrenska Academy</orgName>
								<orgName type="institution">University of Gothenburg</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Maris</forename><surname>Alver</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Estonian Genome Centre</orgName>
								<orgName type="department" key="dep2">Institute of Genomics</orgName>
								<orgName type="institution">University of Tartu</orgName>
								<address>
									<settlement>Tartu</settlement>
									<country key="EE">Estonia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Matthew</forename><surname>Iveson</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Centre for Clinical Brain Sciences</orgName>
								<orgName type="institution">University of Edinburgh</orgName>
								<address>
									<settlement>Edinburgh</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Andreas</forename><surname>Göteson</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="department" key="dep2">Institute of Neuroscience and Physiology at the Sahlgrenska Academy</orgName>
								<orgName type="institution">University of Gothenburg</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Antonio</forename><forename type="middle">F</forename><surname>Pardiñas</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Division of Psychological Medicine and Clinical Neurosciences</orgName>
								<orgName type="laboratory">Centre for Neuropsychiatric Genetics and Genomics</orgName>
								<orgName type="institution">Cardiff University</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Ida</forename><forename type="middle">E</forename><surname>Sønderby</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Precision Psychiatry</orgName>
								<orgName type="department" key="dep2">Division of Mental Health and Addiction</orgName>
								<orgName type="department" key="dep3">Institute of Clinical Medicine</orgName>
								<orgName type="institution" key="instit1">Oslo University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Department of Medical Genetics</orgName>
								<orgName type="institution">Oslo University Hospital</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">KG Jebsen Centre for Neurodevelopmental Disorders</orgName>
								<orgName type="institution" key="instit2">University of Oslo</orgName>
								<orgName type="institution" key="instit3">Oslo University Hospital</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Kevin</forename><forename type="middle">S</forename><surname>O'connell</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Precision Psychiatry</orgName>
								<orgName type="department" key="dep2">Division of Mental Health and Addiction</orgName>
								<orgName type="department" key="dep3">Institute of Clinical Medicine</orgName>
								<orgName type="institution" key="instit1">Oslo University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Qingqin</forename><surname>Li</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Janssen Research and Development</orgName>
								<address>
									<settlement>Neuroscience, Titusville</settlement>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Yi</forename><surname>Lu</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Medical Epidemiology and Biostatistics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Hreinn</forename><surname>Stefánsson</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">deCODE Genetics</orgName>
								<address>
									<settlement>Reykjavik</settlement>
									<country key="IS">Iceland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD</roleName><forename type="first">Kári</forename><surname>Stefánsson</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">University of Iceland</orgName>
								<address>
									<settlement>Reykjavik</settlement>
									<country key="IS">Iceland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Heather</forename><surname>Whalley</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">deCODE Genetics</orgName>
								<address>
									<settlement>Reykjavik</settlement>
									<country key="IS">Iceland</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="laboratory">Centre for clinical brain sciences</orgName>
								<orgName type="institution">University of Edinburgh</orgName>
								<address>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Centre for Medical Informatics</orgName>
								<orgName type="institution" key="instit1">Generation Scotland</orgName>
								<orgName type="institution" key="instit2">University of Edinburgh</orgName>
								<address>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD</roleName><forename type="first">Mikael</forename><surname>Landén</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="department" key="dep2">Institute of Neuroscience and Physiology at the Sahlgrenska Academy</orgName>
								<orgName type="institution">University of Gothenburg</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Department of Medical Epidemiology and Biostatistics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD</roleName><forename type="first">Michael</forename><forename type="middle">C</forename><surname>O´donovan</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Division of Psychological Medicine and Clinical Neurosciences</orgName>
								<orgName type="laboratory">Centre for Neuropsychiatric Genetics and Genomics</orgName>
								<orgName type="institution">Cardiff University</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Knut</forename><surname>Smerud</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution">Smerud Medical Research International AS</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Gerard</forename><forename type="middle">R</forename><surname>Dawson</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">P1vital LTD</orgName>
								<address>
									<settlement>Oxfordshire</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Thomas</forename><surname>Werge</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Institute of Biological Psychiatry</orgName>
								<orgName type="institution" key="instit1">Mental Health Services</orgName>
								<orgName type="institution" key="instit2">Copenhagen University Hospital</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Department of Clinical Medicine</orgName>
								<orgName type="institution">University of Copenhagen</orgName>
								<address>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD) 18</roleName><forename type="first">Alfonso</forename><surname>Buil</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Institute of Biological Psychiatry</orgName>
								<orgName type="institution" key="instit1">Mental Health Services</orgName>
								<orgName type="institution" key="instit2">Copenhagen University Hospital</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD</roleName><forename type="first">Andreas</forename><surname>Reif</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Psychiatry, Psychosomatic Medicine and Psychotherapy</orgName>
								<orgName type="institution">University Medical Centre</orgName>
								<address>
									<settlement>Frankfurt, Frankfurt am Main</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">Fraunhofer Institute for Translational Medicine and Pharmacology ITMP</orgName>
								<address>
									<settlement>Frankfurt am Main</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Lili</forename><surname>Milani</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Estonian Genome Centre</orgName>
								<orgName type="department" key="dep2">Institute of Genomics</orgName>
								<orgName type="institution">University of Tartu</orgName>
								<address>
									<settlement>Tartu</settlement>
									<country key="EE">Estonia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Espen</forename><surname>Molden</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Center for Psychopharmacology</orgName>
								<orgName type="institution">Diakonhjemmet Hospital</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="department">Department of Pharmacy</orgName>
								<orgName type="institution">University of Oslo</orgName>
								<address>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD) 24</roleName><forename type="first">Chiara</forename><surname>Fabbri</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Biomedical and NeuroMotor Sciences</orgName>
								<orgName type="institution">University of Bologna</orgName>
								<address>
									<settlement>Bologna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD</roleName><forename type="first">Alessandro</forename><surname>Serretti</surname></persName>
							<affiliation key="aff24">
								<orgName type="department">Department of Medicine and surgery</orgName>
								<orgName type="institution">Kore University of Enna</orgName>
								<address>
									<settlement>Enna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff25">
								<orgName type="department">27. Social, Genetic and Developmental Psychiatry Centre</orgName>
								<orgName type="institution">Oasi Research Institute-IRCCS</orgName>
								<address>
									<settlement>Troina</settlement>
									<region>Troina</region>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff26">
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD</roleName><forename type="first">James</forename><surname>Walters</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Division of Psychological Medicine and Clinical Neurosciences</orgName>
								<orgName type="laboratory">Centre for Neuropsychiatric Genetics and Genomics</orgName>
								<orgName type="institution">Cardiff University</orgName>
								<address>
									<settlement>Cardiff</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Cathryn</forename><forename type="middle">M</forename><surname>Lewis</surname></persName>
							<affiliation key="aff27">
								<orgName type="institution" key="instit1">NIHR Maudsley Biomedical Research Centre</orgName>
								<orgName type="institution" key="instit2">South London and Maudsley NHS Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, PhD</roleName><forename type="first">Ole</forename><forename type="middle">A</forename><surname>Andreassen</surname></persName>
							<email>ole.andreassen@medisin.uio.no</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Center for Precision Psychiatry</orgName>
								<orgName type="department" key="dep2">Division of Mental Health and Addiction</orgName>
								<orgName type="department" key="dep3">Institute of Clinical Medicine</orgName>
								<orgName type="institution" key="instit1">Oslo University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">KG Jebsen Centre for Neurodevelopmental Disorders</orgName>
								<orgName type="institution" key="instit2">University of Oslo</orgName>
								<orgName type="institution" key="instit3">Oslo University Hospital</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Recommendations for defining treatment outcomes in major psychiatric disorders leveraging real-world data</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2025-06-29T13:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Real-world data</term>
					<term>antidepressants</term>
					<term>antipsychotics</term>
					<term>mood stabilizers</term>
					<term>precision psychiatry</term>
					<term>regulatory decisionmaking</term>
				</keywords>
			</textClass>
			<abstract>
				<p>While information from real-world data (RWD) can be utilized to identify factors able to aid treatment choice, guidelines for the use of RWD are lacking. The aim of this narrative review and expert opinion is to summarize and evaluate definitions of treatment outcomes to antidepressants, antipsychotics, and mood stabilizers using RWD, and to suggest standards for the field. Given that no standards for the use of RWD in estimating treatment outcomes exist, there is a high variability in treatment outcome definitions. We make recommendations for different scenarios of available data and highlight the importance of using other sources of information to validate proxy phenotypes such as continued treatment, switching between medications or polypharmacy of psychotropic medications. Well-defined and validated treatment outcome measures leveraging RWD hold the potential to facilitate the development of precision psychiatry approaches and support regulatory decision-making in psychopharmacological agents. Research in context Evidence before this study There are massive amounts of real-world healthcare data with treatment outcomes that can be applied in data-driven research to identify factors related to outcome, with the ultimate goal of improving pharmacotherapy in psychiatry. Moreover, real-world data can be implemented for pharmacovigilance and drug repurposing to support regulatory decisionmaking. To review the literature on pharmacological treatment outcome definitions from real-world data that have been used for schizophrenia, bipolar disorder, and major depression, PubMed was used to identify articles (up to August 1, 2024) on &quot;real-world data AND [antidepressants OR antipsychotics OR mood stabilizers],&quot; &quot;real-world data AND precision psychiatry,&quot; &quot;electronic health records AND [precision psychiatry OR antidepressants OR antipsychotics OR mood stabilizers],&quot; and &quot;treatment stratification AND psychiatry AND [real-world data OR electronic health records]&quot;. The literature review showed that there is a high variability in treatment outcome definitions, and research findings are difficult to compare. Further, guidelines for estimating treatment outcomes from health registries, hospital records, and self-reports are lacking. Given that no standards for using real-world data exist, there is high variability in treatment outcome definitions, and findings are difficult to compare or meta-analyze. Added value of this study We have reviewed the current literature and presented the different outcome measures applied in previous studies. Building on these findings, we have made recommendations for different real-world scenarios and available data. This is the first attempt to define outcome measures using real-world data, which will form the starting point of a series of studies that can form the basis of an iterative process improving the definitions. We highlight the importance of validating proxy phenotypes using other sources of information. We conclude that well-defined and validated treatment outcome measures leveraging real-world data have the potential to form the basis for developing precision psychiatry approaches and support regulatory decision-making on psychopharmacological treatment. Implications of all the available evidence With the growing interest in AI-tools, there is a need for large training and test data from health care with better quality. Standardization of treatment outcome definitions is important for leverage current research aiming to develop prediction and stratification tools for future precision psychiatry.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The treatment of psychotic and affective symptoms, which are core characteristics of the severe mental disorders schizophrenia (SCZ) <ref type="bibr">1</ref> , bipolar disorder (BIP) <ref type="bibr">2</ref> and major depressive disorder (MDD) <ref type="bibr">3</ref> , remains a significant challenge in psychiatry. Current medications for SCZ mainly include antipsychotics <ref type="bibr">1</ref> , and antidepressants are the main medications used to treat MDD <ref type="bibr">3</ref> . While BIP is primarily treated with lithium and other mood stabilizers 2 , the treatment of BIP is challenging as the different phases of the disorder need different treatment approaches <ref type="bibr">4</ref> . Although psychotropic medications are effective for the majority of patients with psychiatric disorders 5 , there is a large variation in their efficacy and adverse effects <ref type="bibr">6</ref> . Individuals whose symptoms do not meaningfully improve after ≥2 psychotropic drug trials of adequate dose and duration are commonly defined as having treatment-resistant or difficultto-treat conditions <ref type="bibr">6</ref> . Non-response to psychotropic medication is a significant clinical problem, with failure rates of around 30% in SCZ <ref type="bibr">7,</ref><ref type="bibr">8</ref> , BIP <ref type="bibr">9</ref> , and MDD <ref type="bibr">3,</ref><ref type="bibr">10</ref> . However, the rates of treatment resistance are difficult to determine in BIP, as they differ across phases and different episodes <ref type="bibr">4,</ref><ref type="bibr">11</ref> , with depression being associated with greater risk of relapse than mania <ref type="bibr">4,</ref><ref type="bibr">12</ref> . For MDD, the estimated rate of treatment resistance increases to about 55% when symptomatic remission is included in the definition of antidepressant treatment resistance <ref type="bibr">10</ref> .</p><p>Adverse effects to psychotropic medication are common and often cause non-adherence or discontinuation leading to relapse and increased risk for suicide <ref type="bibr">[13]</ref><ref type="bibr">[14]</ref><ref type="bibr">[15]</ref> . For antipsychotics, major adverse effects include sedation, weight gain, and motor (extrapyramidal) symptoms <ref type="bibr">1,</ref><ref type="bibr">13,</ref><ref type="bibr">14</ref> . Common adverse effects of antidepressants include headache, anxiety, agitation, gastrointestinal symptoms, and loss of libido <ref type="bibr">16</ref> . For mood stabilizing treatment, tremor, cognitive impairment, and weight gain are common adverse effects <ref type="bibr">2</ref> . Additional complexity arises from the common use of polypharmacy in psychiatry, increasing the risk for adverse effects and drug-drug interactions <ref type="bibr">17,</ref><ref type="bibr">18</ref> . Guidelines offer limited support for medication choice, given the lack of specific treatment indications and under-exploitation of real-world data (RWD) for treatment outcomes <ref type="bibr">19</ref> . Therefore, psychopharmacological treatments often follow a trial-and-error principle, attempting to balance between therapeutic and adverse effects <ref type="bibr">20</ref> . Existing information from RWD can be leveraged to identify factors able to aid treatment choice, to improve treatment response and reduce adverse effects.</p><p>RWD is defined by the US Food and Drug Administration (FDA) as "the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources" <ref type="bibr" target="#b139">21</ref> . The European Medicines Agency (EMA) defines RWD as "routinely collected data relating to a patient's health status or the delivery of health care from a variety of sources other than traditional clinical trials" <ref type="bibr">22</ref> . According to the European Medicines Regulatory Network (EMRN) strategy, by 2025, the use of RWD will have been enabled and the value of RWD will have been established across regulatory use cases, to support the development and use of better medicines for patients <ref type="bibr">23,</ref><ref type="bibr" target="#b142">24</ref> . RWD from health registries and hospital records/electronic health records (eHRs), laboratory databases, as well as self-reported drug use and related treatment response can provide large-scale data to study treatment outcomes in psychiatric disorders. From nationwide prescription records, treatment response can be estimated from proxy phenotypes, for example based on the duration and changes in type and dosage of medication <ref type="bibr">25</ref> . These data sources are essential for the advancement of precision medicine treatment in psychiatry, as they provide the large-scale data needed to develop and validate clinical prediction models of treatment outcomes <ref type="bibr">26</ref> .</p><p>As illustrated in <ref type="figure" target="#fig_1">Supplementary Figure 1</ref> (Appendix), RWD have the potential to both facilitate precision psychiatry and to support regulatory decision-making on psychopharmacological treatment. However, no standards exist for use of RWD to analyze treatment response, and there is high variability in treatment outcome definitions using RWD. In randomized controlled trials (RCTs) or other clinical studies, treatment response is standardly assessed using disease specific rating scales and treatment adherence is closely monitored. In contrast, RWD are subject to high variability and confounders, especially when proxy phenotypes are used to estimate treatment outcomes. Improvement of using proxies in large datasets and standardization of treatment outcome measures using RWD is therefore needed. The aim of this narrative review and expert opinion is to summarize and evaluate definitions of treatment outcomes to antidepressants, antipsychotics, and mood stabilizers using RWD, and to propose standards for the field.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>To review the literature on pharmacological treatment outcome definitions from RWD that have been used for SCZ, BIP, and MDD, PubMed was used to identify articles (up to August 1, 2024) on "real-world data AND [antidepressants OR antipsychotics OR mood stabilizers]," "real-world data AND precision psychiatry," "electronic health records AND [precision psychiatry OR antidepressants OR antipsychotics OR mood stabilizers]," and "treatment stratification AND psychiatry AND [real-world data OR electronic health records]". We searched the literature to qualitatively evaluate relevance to the current objective and selected papers based on their relevance for treatment outcome measures to be included in a non-systematic narrative review. We brought together a group of international experts (including psychiatrists, pharmacologists, epidemiologists, and researchers with extensive experience in RWD research). We had monthly online meetings from November 2023 to September 2024 to review the literature, select papers, and to discuss the structure and content of the recommendations. We finalized the work at an in-person meeting in October 2024. Using expert opinion, we evaluated treatment outcome measures using RWD, suggested validation for proxy phenotypes and proposed plans for better use of currently available data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definitions of treatment outcomes from real-world data: Challenges and opportunities</head><p>Guidelines to define pharmacological treatment outcomes in psychiatry are mostly based on clinical measures such as symptom rating scales, which are widely applied in clinical studies <ref type="bibr">6</ref> . While guidelines for the use of RWD are lacking, proxy measures such as continued treatment, switching between psychotropic medications or polypharmacy have been applied to assess treatment outcomes. Definitions used for these proxy measures of pharmacological treatment outcomes using RWD in MDD, SCZ, and BIP are summarized in <ref type="table" target="#tab_0">Supplementary  Table 1</ref> (Appendix).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antidepressants</head><p>To define treatment outcomes in MDD, switching between antidepressant drugs has been widely applied as a proxy for non-response in RWD research <ref type="bibr" target="#b24">[27]</ref><ref type="bibr" target="#b25">[28]</ref><ref type="bibr" target="#b26">[29]</ref><ref type="bibr" target="#b27">[30]</ref><ref type="bibr" target="#b28">[31]</ref><ref type="bibr" target="#b29">[32]</ref><ref type="bibr" target="#b30">[33]</ref><ref type="bibr" target="#b31">[34]</ref><ref type="bibr" target="#b32">[35]</ref> , although switching can result from both lack of treatment effect and adverse effects. Treatment-resistant depression (TRD) is widely used as an outcome variable, broadly defined as ≥2 switches between antidepressant drugs prescribed for an adequate duration in individuals diagnosed with a depressive disorder <ref type="bibr">10,</ref><ref type="bibr" target="#b24">27,</ref><ref type="bibr" target="#b25">28,</ref><ref type="bibr" target="#b27">[30]</ref><ref type="bibr" target="#b28">[31]</ref><ref type="bibr" target="#b29">[32]</ref><ref type="bibr" target="#b30">[33]</ref><ref type="bibr" target="#b31">[34]</ref><ref type="bibr" target="#b32">[35]</ref><ref type="bibr" target="#b33">[36]</ref> . In some studies, both duration and dose have been considered <ref type="bibr" target="#b25">28,</ref><ref type="bibr" target="#b29">32,</ref><ref type="bibr" target="#b30">33</ref> . However, the criteria for defining adequate dose and duration vary between studies. In other studies, TRD has been defined based on use of electroconvulsive therapy (ECT) derived from register data or medical records <ref type="bibr" target="#b34">[37]</ref><ref type="bibr" target="#b35">[38]</ref><ref type="bibr" target="#b36">[39]</ref> . Using RWD, treatment stability has been defined as continued prescription of an antidepressant, for example for ≥90 days, as a proxy for treatment effectiveness <ref type="bibr" target="#b37">40</ref> . In contrast, the time needed to assess treatment response in clinical trials is 4-12 weeks <ref type="bibr">15</ref> . Antidepressant duration as a continuous measure, in terms of number of prescriptions or weeks of prescription, was used as a proxy for antidepressant response based on UK Biobank data, in addition to various measures of antidepressant switching and discontinuation <ref type="bibr" target="#b38">41</ref> . Treatment response has also been defined by using eHRs from a clinical register that gathers clinical information across hospitals, where clinical notes were used to identify evidence of improvement applying a deep learning-based text classification model 42 . Using a similar approach, TRD has been defined as ≥2 depressionrelated visits within a 12-month period following an initial antidepressant prescription and ≥2 antidepressants during this period, using eHRs <ref type="bibr" target="#b40">43</ref> . In a genome-wide association study (GWAS), both antidepressant switching and questionnaire data have been used to define TRD, and questionnaire data was used to define antidepressant response <ref type="bibr" target="#b41">44</ref> . In that study <ref type="bibr" target="#b41">44</ref> , TRD was defined as non-response to ≥2 antidepressants taken for at least 5-6 weeks, and non-TRD was defined as response to either the first or second medication taken for at least 3-4 weeks <ref type="bibr" target="#b42">45</ref> . In most other studies on TRD, the non-TRD group includes all individuals not meeting the criteria for the TRD group. In a recent GWAS on antidepressant non-response, data from rating scales for depressive symptoms, questionnaires of treatment effect, and data from eHRs have been combined to increase sample size <ref type="bibr" target="#b43">46</ref> . However, switching antidepressants may be independent from response, for example at least in some cases it may be due to side effects or lack of compliance. It should also be noted that antidepressant continuation is not always a reliable indicator of response but could reflect inertia or lack of clinical follow-up despite poor response <ref type="bibr" target="#b30">33,</ref><ref type="bibr" target="#b45">47</ref> . Moreover, different antidepressant classes are often grouped into one analysis category, but, even within the same class, antidepressants may differ considerably in their mechanism of action 3 . Furthermore, antidepressants are frequently prescribed for conditions other than depression, highlighting the importance of supplementing with diagnostic information, which is not always considered in RWD-based studies. In addition, co-morbidities may facilitate the development of TRD. It has been shown that individuals with comorbid posttraumatic stress disorder (PTSD) were less likely to achieve remission from MDD after antidepressant treatment <ref type="bibr" target="#b46">48</ref> . Other factors that could increase the risk of developing non-remission after antidepressant treatment include hospitalization for suicide crisis, attempts or other episodes of self-harm <ref type="bibr" target="#b47">49,</ref><ref type="bibr" target="#b48">50</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antipsychotics</head><p>Previous studies investigating treatment outcomes in SCZ have mainly focused on treatmentresistance. Clozapine is the only evidence-based medication for treatment-resistant SCZ, which is characterized by a failure of response to at least two antipsychotic trials of adequate dose and duration <ref type="bibr">8,</ref><ref type="bibr" target="#b49">51</ref> . As it is primarily used for treatment-resistant SCZ, clozapine has been widely used in research as a proxy measure for non-response/treatment resistance both using clinical data and RWD <ref type="bibr">6,</ref><ref type="bibr">8</ref> . In a study using eHRs, treatment-resistant SCZ was defined as either use of clozapine or prescription of a third new antipsychotic after two different antipsychotic prescriptions for ≥6 weeks <ref type="bibr" target="#b50">52</ref> . Use of clozapine or antipsychotic polypharmacy defined as ≥2 antipsychotics for ≥90 days has been used as a proxy for treatment-resistant SCZ in a Swedish register study <ref type="bibr" target="#b51">53</ref> . However, prescribing guidelines stating that polypharmacy should only be considered after first trying clozapine are not consistently applied in clinical practice <ref type="bibr" target="#b52">54</ref> . Therefore, inclusion of polypharmacy as a criterion for treatment-resistant SCZ may increase the number of false positives. Another issue is potential pseudo-resistance, where lack of response can result from sub-therapeutic medication levels due to poor adherence or metabolic status <ref type="bibr" target="#b53">55,</ref><ref type="bibr" target="#b54">56</ref> , supporting the utility of therapeutic drug monitoring (TDM). In Danish population registry data, treatment-resistant SCZ was defined as clozapine initiation or hospitalization due to SCZ during antipsychotic treatment within 18 months after ≥2 periods of different antipsychotic monotherapies, each lasting ≥6 weeks <ref type="bibr" target="#b55">57,</ref><ref type="bibr" target="#b56">58</ref> . Both cases receiving clozapine and those who were not treated with this drug but still showed evidence of poor response to multiple antipsychotics are captured in these phenotypes of resistance. In a study using the UK mandatory monitoring system for clozapine users, treatment-resistant SCZ was defined as a clinician reported diagnosis of treatment-resistant SCZ <ref type="bibr" target="#b57">59</ref> . There are several considerations when using clozapine as a proxy phenotype for non-response or treatment resistance. The control group (individuals with SCZ who never used clozapine) could still include individuals with poor treatment response or resistance, as clozapine is prescribed only to a fraction of patients with non-response to ≥2 antipsychotics <ref type="bibr" target="#b58">60</ref> . Moreover, clozapine prescription rates differ by country <ref type="bibr" target="#b59">61</ref> , sex 62 and ethnicity <ref type="bibr" target="#b61">63</ref> . Finally, a minority of patients eligible for clozapine starts this treatment, mostly for issues linked to side effects and the need for regular blood monitoring <ref type="bibr" target="#b62">64</ref> . Using data from eHRs, ultra-treatment-resistant SCZ (i.e. non-response to clozapine) has been defined as readmission following an inpatient episode where the patient was discharged on clozapine <ref type="bibr" target="#b63">65</ref> . Moreover, hospitalization or an emergency department attendance has been widely used as a proxy for relapse when using eHRs <ref type="bibr" target="#b64">[66]</ref><ref type="bibr" target="#b65">[67]</ref><ref type="bibr" target="#b66">[68]</ref> . One of these studies attempted to remove nonadherent patients, by excluding those who had fewer than 90 days of stable prescription of antipsychotic monotherapy before the study start date <ref type="bibr" target="#b66">68</ref> . However, these studies may include hospitalization or emergency department attendance for other reasons such as drug-induced psychosis or suicide attempts.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Lithium and other mood stabilizers</head><p>BIP is characterized by episodes of distinct groups of symptoms 2 , and its treatment is more multimodal compared to MDD and SCZ <ref type="bibr">2,</ref><ref type="bibr">4</ref> , making treatment outcomes more difficult to define. Previous studies investigating treatment outcomes in BIP mainly include studies of lithium response assessed by the Alda scale ("Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder") <ref type="bibr" target="#b67">69</ref> , and consensus definitions of treatment outcomes in BIP are based on the use of clinical assessments <ref type="bibr">4,</ref><ref type="bibr">11,</ref><ref type="bibr" target="#b68">70</ref> . In cohorts where clinical information such as symptom rating scales is not available, registry data has been used to define lithium non-response, to find alternative definitions to those based on clinical evaluation. In a nationwide register-based study from Denmark 71 , lithium nonresponse was defined as hospitalization at a psychiatric ward or prescription of a second psychotropic drug within six months after starting lithium treatment, whereas lithium monotherapy for more than six months without hospitalization was considered as indicative of response. Questionnaire data have also been used to define lithium response <ref type="bibr" target="#b70">72</ref> . However, data on subjective treatment outcomes may be biased by factors such as comorbid disorders and treatment non-adherence, which should be considered when defining treatment outcomes <ref type="bibr">4</ref> . This has been demonstrated in a study assessing factors associated with selfperceived treatment-resistance in BIP, showing that a large proportion of patients had symptoms of comorbid mental disorders that were regarded as treatment-resistant bipolar symptoms while other patients did not receive adequate treatment or did not adhere to the treatment <ref type="bibr" target="#b71">73</ref> . Recent results from the SUPER-Finland psychosis study have shown that a group of severely affected individuals with BIP later received the diagnosis of SCZ 74 , suggesting that initial misdiagnosis can confound the interpretation of failed treatment response in RWD. Moreover, experts have proposed that lithium response should be defined in the context of level of lithium exposure, e.g., dose, treatment duration, adherence, plasma levels, and adjunctive treatments <ref type="bibr" target="#b73">75</ref> . Using eHR data, treatment failure of mood stabilizers has been defined as time to discontinuation of the medication or add-on of another mood stabilizer, antipsychotic, antidepressant or benzodiazepine <ref type="bibr" target="#b74">76</ref> . However, bipolar depressive episodes are often treated with off-label medications, and it has been argued that definitions similar to those used for unipolar depression should be avoided, because the pathogenesis of bipolar depression are different from unipolar depression <ref type="bibr" target="#b75">77</ref> . Other outcome measures such as occupational dysfunction and hospital admissions may be a preferable proxy phenotype for non-response to maintenance treatment in BIP, because these are indicative of relapse <ref type="bibr" target="#b76">78</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definitions of treatment outcomes from real-world data: Expert opinion and recommendations</head><p>RWD from health registries and hospital records/eHRs as well as self-reports can provide large-scale data needed for prediction and stratification of treatment outcomes in psychiatry research <ref type="bibr">26</ref> . However, RWD are subject to variability and confounders, requiring careful curation and validation to increase the specificity of treatment outcome measures. RCTs are considered the gold standard for assessing treatment effects, as patients are randomly assigned to receive an intervention <ref type="bibr" target="#b77">79</ref> and provide longitudinal symptom measures to examine change across time with a particular treatment. However, RCTs may not be representative of the whole clinical population <ref type="bibr" target="#b78">80</ref> , a known fact leading to the over-estimation of the effects of many drug treatments in comparison to real-world scenarios <ref type="bibr" target="#b79">81</ref> . Patients in RCTs are generally healthier than in the real world, in part because of the need for informed consent, which can be difficult to obtain during the acute phase of the illness. Individuals with psychiatric and somatic co-morbidities who are treated with several drugs (polypharmacy) are usually excluded from RCTs, because they are at greater risk of developing drug-drug interactions and adverse effects. Similarly, suicidal ideation, substance use, and advanced age are commonly considered exclusion criteria. In addition, treatment adherence is better in RCTs than in the real world <ref type="bibr" target="#b80">82</ref> . Thus, RWD provide a unique opportunity to validate findings from RCTs (short term, monotherapy) in real-world settings (long term, co-morbidities, polypharmacy) <ref type="bibr" target="#b81">83</ref> , e.g., to study the long-term effects of ketamine/esketamine in TRD <ref type="bibr" target="#b82">84,</ref><ref type="bibr" target="#b83">85</ref> . Moreover, RWD can be complementary to RCT to evaluate treatment effectiveness, because RWD reflect the reality of health care, providing insights into trajectories of pharmacotherapy and both psychiatric and somatic co-morbidities <ref type="bibr">26</ref> .</p><p>However, the complex and heterogeneous nature of RWD makes it challenging to define treatment outcomes. Heterogeneity in RWD may arise from a variety of differences between countries, health care systems, practitioners, and type of data source (primary care, specialist care, hospitals). In addition, RWD from any single source, e.g., from prescription registries, may be incomplete and unstructured. Linkage to other registries can help refine treatment outcome definitions based on prescription registry data by incorporating additional information such as hospitalization during pharmacological treatment. In the Nordic countries, including Denmark, Finland, Iceland, Estonia, Norway, and Sweden, prescription databases can be linked to other health registries <ref type="bibr" target="#b84">86</ref> . Studies based on the Nordic prescription databases have yielded new knowledge on the beneficial and adverse effects of drug use in real-world settings <ref type="bibr">25</ref> . Routinely collected information in eHRs and population-wide health registries can provide information about diagnosis and co-morbidities, but also sociodemographic information and functional outcomes such as cause of death, sick leave and employment status, hospitalizations, as well as anthropometric and blood measures such as lipid levels. Linking these data to prescribed drugs for longitudinal observations, can provide proxies for treatment outcomes such as wellbeing and functioning as well as adverse effects from specific drugs, e.g., weight gain 87 , hypertension or hyperlipidemia.</p><p>For the definition of proxy phenotypes of treatment response using prescription registries, it is important to consider diagnostic information, dose, duration of treatment, and information about the indication for drug prescription. Whereas diagnostic information can be retrieved from other health registries, and dose and duration can be derived from the prescription registry, information about indication is often missing on prescriptions. However, diagnostic information can serve as a proxy of the indication of psychotropic medications. While diagnostic information in registries from the International Classification of Diseases (ICD) may be subject to variability, clinical validation of registered diagnoses has demonstrated high consistency with diagnoses based on structured interviews, indicating that registry data can provide reliable diagnostic information <ref type="bibr" target="#b86">88,</ref><ref type="bibr" target="#b87">89</ref> . Moreover, the indication of psychotropic medications can often be estimated from the dosage of the drug, e.g., it is common to use low-dose of some antidepressants for sleep <ref type="bibr" target="#b88">90</ref> or low-dose of antipsychotics to treat behavioral and psychological symptoms in dementia <ref type="bibr" target="#b89">91</ref> , so these prescriptions should not be considered as treatment of MDD, BIP, or SCZ. Natural language processing (NLP) <ref type="bibr" target="#b90">92</ref> can be applied to free text in prescriptions and can also be used to retrieve information on the indication of the prescribed drug. NLP, through the development of artificial intelligence algorithms known as language models, is also well-suited for extracting information from general text records <ref type="bibr" target="#b90">92</ref> , and can thus be used for extraction of free text from unstructured routine health data to capture symptom improvement or other more complex treatmentrelated phenotypes. When using prescription registries where dose information is missing, the daily dose can be calculated from the amount of the purchased drug and time between purchases. It has been shown that information from these dose calculations can be used to address clinically useful research questions on antipsychotic treatment outcomes <ref type="bibr" target="#b91">93</ref> . It has also been shown that proxies of poor compliance to antidepressant treatment can be calculated by the proportion of adequate prescription intervals, defined by 14 weeks or less between subsequent antidepressant prescriptions 27 .</p><p>It should be noted that treatment outcome measures derived from RWD such as prescription registries are still proxy phenotypes, even though various RWD sources are combined to refine these proxy measures. Moreover, there are potential limitations that are difficult to address, e.g., the use of diagnostic information as a proxy for indication of psychotropic medications may be biased by co-morbidities such as PTSD or borderline personality disorder. However, it could be argued that distinct polypharmacy profiles for specific diagnoses could be used as proxies for non-response, but there is little research on this topic, and it is difficult to rule out polypharmacy due to specific symptom profiles. While ensuring adequate treatment duration may reduce confounders, it remains difficult to address immortal time bias, referring to a period of follow-up during which death or the study outcome cannot occur <ref type="bibr" target="#b92">94</ref> . Therefore, it is important to consider treatment duration in both non-responders and responders, to minimize errors in estimating the association between treatment and outcome <ref type="bibr" target="#b93">95</ref> . Our recommendations for defining treatment outcomes in major psychiatric disorders leveraging population-wide health registries and routinely collected questionnaires/self-reports are summarized in <ref type="table" target="#tab_0">Tables 1-3</ref> and Boxes 1-3. Recommendations for measuring psychopharmacological treatment outcomes using free text from electronic health records are summarized in <ref type="figure">Supplementary Table 2</ref> (Appendix). These recommendations are suggestions for better use of proxy measures. When applying switching between psychotropic medications as a proxy measure of treatment resistance, the medication class has not been included in our recommendations. While others have suggested definitions based on different classes of antipsychotics or antidepressants, the supporting evidence for including different classes is weak <ref type="bibr">6</ref> . The definition of TRD involving different antidepressant classes is not supported by many consensus guidelines, including EMA <ref type="bibr">10,</ref><ref type="bibr" target="#b94">96,</ref><ref type="bibr" target="#b95">97</ref> . We make recommendations for different RWD sources to achieve improved outcome measures. For example, when using treatment duration of ≥6 weeks as a criterion to define antidepressant switching as a proxy for non-response, switches due to side effects will be reduced while some side-effects-related switches may also occur after 6 weeks. Likewise, stable treatment with the same drug does not always reflect treatment response. Therefore, validation of proxy measures becomes important to evaluate the potential of RWD for clinical application. Whereas definitions of TRD from RWD have been compared with definitions from clinical data <ref type="bibr" target="#b96">98,</ref><ref type="bibr" target="#b97">99</ref> , findings from studies using RWD to define and predict treatment outcomes should be replicated and validated using other sources of information such as questionnaires. In the Estonian Biobank <ref type="bibr" target="#b98">100,</ref><ref type="bibr" target="#b99">101</ref> , data from prescription and other registries as well as questionnaire data on treatment response is available, thus definitions of treatment response using prescription registry data can be validated using the questionnaire data. In Finland, the Social Insurance Institution of Finland's national medical drug purchase registry can be used to define treatment outcomes, which can be validated in the recently recruited SUPER-Finland psychosis study <ref type="bibr" target="#b100">102</ref> . Convincing results from the SUPER-Finland study have shown that longitudinally tracking psychiatric hospital burden is a feasible method to assess longitudinal disease trajectories. Psychiatric hospital burden was strongly associated with RWD measures such as clozapine use, global function at discharge, and cognitive performance <ref type="bibr" target="#b72">74</ref> . These results suggest that response to drug treatment could be adequately assessed using linked registry data. In a recent study, Patient Health Questionnaire scores have been used for validation of proxy phenotypes of antidepressant treatment outcomes, showing that antidepressant switching and treatment with add-on medications were strongly associated with higher depression severity scores <ref type="bibr" target="#b101">103</ref> . Other samples that can be used for validating treatment outcome definitions from RWD include quality registries such as the Swedish National Quality Register for bipolar disorder 81 that contain data on patient problems, medical interventions, and outcomes after treatment, the UK Biobank 104 that includes mental health and treatment response questionnaires, and the All of US Research program <ref type="bibr" target="#b103">105</ref> including multitudinous data from eHRs and questionnaires. Moreover, it should be investigated how the definitions differ among countries, e.g., the proportion of individuals that fall under a specific definition, to determine if proxy measures of treatment outcomes from RWD are comparable across countries. Taken together, RWD from registries and health care systems with potential for record-linkage combined with questionnaire data and selfreports on medication response and adverse effects could provide clinically useful treatment outcome measures in major psychiatric disorders.</p><p>It is widely accepted that RWD are more generalizable than evidence from standardized clinical trial data, because RWD more likely reflect real treatment effects <ref type="bibr" target="#b104">106</ref> . Regulatory agencies such as EMA have increasingly considered the use of RWD complementary to evidence from RCTs to support regulatory decision-making <ref type="bibr" target="#b105">107,</ref><ref type="bibr" target="#b106">108</ref> . To date, RWD has been used primarily in post-approval settings to monitor drug safety and detect adverse events as well as to support dose modifications, and complementary RWD evidence may be useful in assessing the feasibility of new indications <ref type="bibr" target="#b105">[107]</ref><ref type="bibr" target="#b106">[108]</ref><ref type="bibr" target="#b107">[109]</ref> . RWD can be leveraged to capture long-term treatment outcomes to complement RCTs to evaluate safety and effectiveness, especially when the treatment outcomes and related safety require longer follow-up durations, e.g., functional outcomes, hospitalization, and suicide. In a Swedish registry study <ref type="bibr" target="#b108">110</ref> , it has been demonstrated that patients with attention deficit-hyperactivity disorder (ADHD) had reduced rates of criminality when receiving ADHD medications <ref type="bibr" target="#b108">110</ref> . Another Swedish registry study showed that patients with BIP receiving antidepressant monotherapy had an increased risk of mania compared to patients receiving an antidepressant in combination with a mood stabilizer <ref type="bibr" target="#b109">111</ref> . Moreover, RWD could provide additional evidence to support regulatory decision-making for new indications of existing drugs, known as repurposing. Computational drug repurposing for psychiatric disorders has gained increasing interest in research <ref type="bibr" target="#b110">[112]</ref><ref type="bibr" target="#b111">[113]</ref><ref type="bibr" target="#b112">[114]</ref><ref type="bibr" target="#b113">[115]</ref><ref type="bibr" target="#b114">[116]</ref> . However, it has been difficult to validate the effectiveness of the suggested repurposing candidates in psychiatric disorders. RWD such as lifetime health registries could be used to screen for associations between use of repurposing candidates and reduced risk of psychiatric disorders 117 as well as for characterization of treatment outcomes including long-term outcomes such as hospitalization and suicide as well as health-economic aspects such as sick leave. Before implementing RWD for pharmacovigilance and drug repurposing, the outcome measures must be well-defined and validated in research. For research using RWD, privacy protection for individuals contributing to RWD must be addressed by data protection legislation <ref type="bibr" target="#b116">118</ref> . Secure data systems for Trusted Research Environments (TRE) must be implemented to ensure that the RWD are impossible to identify and the data are securely handled, e.g., in the UK, OpenSAFELY (https://opensafely.org/) is a TRE where approved researchers never have direct access to real data. In Europe, secure data handling environments must align with requirements from the GDPR and upcoming European Health Data Space (EHDS), particularly when databases are cross-linked.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>RWD from different sources has the potential to both solve the need for large-scale data and provide treatment outcome measures that can be applied in research aiming to improve pharmacotherapy in mental disorders. The definition of proxies for treatment outcomes can be improved by integrating RWD from various registries and health care systems that can be linked to questionnaire data and self-reports on medication response and adverse effects. We make recommendations for different scenarios and available data and highlight the importance of validating proxy phenotypes using other sources of information such as questionnaires. Well-defined and validated treatment outcome measures leveraging RWD have the potential to facilitate precision psychiatry and support regulatory decision-making on pharmacological treatment in psychiatry.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Contributors</head><p>OAA conceived the study. EK drafted the initial manuscript. All authors contributed to the interpretation and editing of the manuscript.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis</head><p>Diagnosis of MDD is required and should be obtained from specialist (alterna8vely primary) health care (ICD10).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>An8depressant treatment</head><p>Medica8on use from prescrip8on registry: ATC codes N06A, as well as ketamine (N01AX03) and esketamine (N01AX14).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Indica8on</head><p>Indica8on can be extracted from free text of prescrip8ons. Other indica8ons than depression (e.g., pain or sleeping problems) should not be considered as an8depressant treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>An8depressant switching</head><p>Medica8on use from prescrip8on registry (ATC codes N06A): To define TRD, it should be ≥2 an8depressant switches, and each switch should between 6 weeks (for adequate treatment dura8on) and 14 weeks (to exclude treatment interrup8on) of the previous an8depressant prescrip8on. Augmenta8on/ combina8on therapy Augmenta8on of or combina8on with another an8depressant or an8psycho8c or lithium.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stable treatment</head><p>Treatment for ≥6 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequate treatment dura8on</head><p>Obtained from prescrip8on registry: Should be ≥6 weeks to reduce the risk of switches due to side effects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequate dose</head><p>Daily dose from prescrip8on registry: Should have minimal dose recommended for major depression.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hospitaliza8on</head><p>Hospitaliza8on due to a depressive episode; should be during or shortly a[er an8depressant treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comorbidity</head><p>Other psychiatric diagnoses should be excluded if these are the main diagnosis (e.g., BIP).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuros8mula8on (ECT or TMS)</head><p>Neuros8mula8on should be during an8depressant treatment. (Es)ketamine treatment Treatment with ketamine/esketamine should be during an8depressant treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adherence</head><p>Ra8o between prescribed and dispensed medica8on can be calculated to es8mate adherence. Non-adherence should be excluded. Rou8nely collected ques8onnaires/ selfreports An8depressant treatment or treatment with (es)ketamine Pa8ent-reported medica8on history can be used if register data is incomplete.</p><p>Treatment nonresponse/resistance Self-reported non-response a[er ≥2 an8depressant trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Side effects</head><p>Switches due to side effects should not be considered as non-response.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adherence</head><p>Adherence measured using pa8ent reports should only be used when no other adherence measures such as drug concentra8ons from therapeu8c drug monitoring are available. From TDM, non-detectable drug concentra8ons can be used as indicator of non-adherence. Non-adherence should be excluded.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis</head><p>Diagnosis of SCZ is required and should be obtained from specialist health care alterna8vely from primary care (ICD10).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Life8me clozapine treatment</head><p>Medica8on use from prescrip8on registry (ATC code N05AH02) or from clozapine registries. An8psycho8c switching Medica8on use from prescrip8on registry (ATC codes N05A): To define treatment resistance, it should be ≥2 an8psycho8c switches, and each switch should between 6 weeks (for adequate treatment dura8on) and 14 weeks (to exclude treatment interrup8on) of the previous an8psycho8c prescrip8on. Stable treatment (as proxy for response)</p><p>Treatment for ≥6 months of the same an8psycho8c.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequate treatment dura8on</head><p>Obtained from prescrip8on registry: Should be ≥6 weeks to reduce the risk of switches due to side effects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequate dose</head><p>Daily dose from prescrip8on registry: Should have minimal dose recommended for SCZ.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hospitaliza8on</head><p>Hospitaliza8on due to SCZ; should be during an8psycho8c treatment ECT ECT should be during an8psycho8c treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comorbidity</head><p>Other psychiatric diagnoses should be excluded if these are the main diagnosis. Adherence Using prescrip8on registry data, the ra8o between prescribed and dispensed medica8on can be calculated to es8mate adherence. From TDM, non-detectable drug concentra8ons can be used as indicator of nonadherence. Non-adherence should be excluded. Rou8nely collected ques8onnaires/ selfreports</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Life8me clozapine treatment</head><p>Pa8ent-reported medica8on history can be used if register data is incomplete.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment nonresponse/resistance</head><p>Self-reported non-response a[er ≥2 an8psycho8c trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Side effects</head><p>Switches due to side effects should not be considered as non-response.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adherence</head><p>Adherence measured using pa8ent reports should only be used when no other adherence measures such as drug concentra8ons from therapeu8c drug monitoring are available. Non-adherence should be excluded.   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis</head><p>Diagnosis of BIP is required and should be obtained from specialist health care, alterna8vely primary health care (ICD10).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bipolar treatment</head><p>Medica8on use from prescrip8on registry: ATC code N05AN01 (lithium), N03A (an8epilep8cs), N05A (an8psycho8cs) and N06A (an8depressants), as well as ketamine (N01AX03) and esketamine (N01AX14).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Polypharmacy</head><p>Non-response/resistance in maintenance treatment: Combined treatment with ≥3 medica8ons to treat BIP (lithium, an8epilep8cs, an8psycho8cs, an8depressants). Non-response/resistance in mania: Combined treatment with ≥3 an8-manic drugs (lithium, an8epilep8cs, an8psycho8cs with indica8on for mania). Non-response/resistance in bipolar depression: ≥3 an8depressant treatments (an8depressants, an8epilep8cs, ketamine, an8psycho8cs with indica8on for bipolar depression).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Medica8on switching</head><p>Non-response/resistance in maintenance treatment: Should be ≥2 switches between different medica8ons to treat BIP (lithium, an8epilep8cs, an8psycho8cs, an8depressants), regardless of monotherapy or combina8on therapy. Non-response/resistance in mania: Should be ≥2 switches between different medica8ons to treat mania (lithium, an8epilep8cs, an8psycho8cs with indica8on for mania), regardless of monotherapy or combina8on therapy. Non-response/resistance in bipolar depression: Should be ≥2 switches between an8depressant treatments (an8depressants, an8epilep8cs, ketamine, an8psycho8cs with indica8on for bipolar depression), regardless of monotherapy or combina8on therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Life8me clozapine treatment</head><p>Medica8on use from prescrip8on registry: ATC code N05AH02.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stable treatment (maintenance)</head><p>Treatment for ≥6 months with 1-2 drugs to treat BIP (lithium, an8epilep8cs, an8psycho8cs, an8depressants).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequate treatment dura8on</head><p>Obtained from prescrip8on registry: Should be ≥6 weeks to reduce the risk of switches due to side effects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequate dose</head><p>Daily dose from prescrip8on registry: Should have minimal dose recommended for BIP.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hospitaliza8on</head><p>Hospitaliza8on during mania (to iden8fy manic episodes) or during bipolar depression (to iden8fy depressive episodes) or during maintenance treatment for BIP (to iden8fy treatment strategies that failed to prevent future episodes).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comorbidity</head><p>Other psychiatric diagnoses should be excluded if these are the main diagnosis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Func8onal outcomes</head><p>Func8onal outcomes such as employment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuros8mula8on (ECT or TMS)</head><p>Neuros8mula8on should be during pharmacological treatment for BIP. (Es)ketamine treatment Treatment with ketamine/esketamine should be during a depressive episode (to define non-response/resistance in bipolar depression).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adherence</head><p>Ra8o between prescribed and dispensed medica8on can be calculated to es8mate adherence. From TDM, nondetectable drug concentra8ons can be used as indicator of non-adherence. Non-adherence should be excluded. Rou8nely collected ques8onnaires/ selfreports</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bipolar treatment</head><p>Pa8ent-reported medica8on history can be used if register data is incomplete.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Polypharmacy</head><p>Pa8ent-reported history on combina8on treatment for BIP (lithium/mood stabilizers, an8psycho8cs, an8depressants) to define non-response/resistance in mania, depression, maintenance (same criteria as for registry data).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Life8me clozapine treatment</head><p>Pa8ent-reported medica8on history can be used if register data is incomplete. Treatment nonresponse/resistance Self-reported non-response a[er ≥2 trials of pharmacological treatment for BIP to define nonresponse/resistance in mania, depression, maintenance (same criteria as for registry data).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Func8onal outcomes</head><p>Pa8ent-reported informa8on about func8onal outcomes such as employment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Side effects</head><p>Switches due to side effects should not be considered as non-response.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adherence</head><p>Adherence measured using pa8ent reports should only be used when no other adherence measures such as drug concentra8ons from therapeu8c drug monitoring are available. Non-adherence should be excluded.  Not considered or not specified <ref type="bibr">4,</ref><ref type="bibr">5</ref> At least 8 weeks <ref type="bibr">6</ref> 60-180 days <ref type="bibr">7</ref> 28-180 days <ref type="bibr">8,</ref><ref type="bibr">9</ref> Time interval Within 1 year 4 Within 2 years <ref type="bibr">6</ref> Within an MDD episode <ref type="bibr">5,</ref><ref type="bibr">7</ref> Not considered or not specified <ref type="bibr">1-4, 8, 9</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose</head><p>Not considered or not specified <ref type="bibr">1,</ref><ref type="bibr">[3]</ref><ref type="bibr">[4]</ref><ref type="bibr">[5]</ref><ref type="bibr">[7]</ref><ref type="bibr">[8]</ref><ref type="bibr">[9]</ref> Daily dose at least the minimum recommenda1ons given for MDD 2 Each trial sa1sfying the condi1on of exceeding 56 defined daily doses within an 8-week period 6 Diagnosis Diagnos1c code (ICD 9/10) for a depressive disorder, and no codes for bipolar, psycho1c disorder etc. ≥6 weeks <ref type="bibr">16,</ref><ref type="bibr">17</ref> Time interval Hospitaliza1on during an1psycho1c treatment (within 18 months) <ref type="bibr">16,</ref><ref type="bibr">17</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose</head><p>Not considered or not specified <ref type="bibr">16,</ref><ref type="bibr">17</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis</head><p>Diagnos1c code (ICD 9/10) for SCZ <ref type="bibr">16,</ref><ref type="bibr">17</ref> Clozapine treatment or ≥2 an1psycho1c trials Dura1on (per non-clozapine an1psycho1c) ≥6 weeks 18 ≥90 days <ref type="bibr">19</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Time interval</head><p>Not considered or not specified <ref type="bibr">18,</ref><ref type="bibr">19</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose</head><p>Not considered or not specified <ref type="bibr">18,</ref><ref type="bibr">19</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis</head><p>Diagnosis of SCZ, schizotypal or delusional disorder (ICD-10 codes F20-F29) <ref type="bibr">18</ref> ICD code for SCZ <ref type="bibr">19</ref> Other criteria Prescrip1on of a third new an1psycho1c <ref type="bibr">19</ref> Registra1on in a mandatory clozapine monitoring system Dura1on (per non-clozapine an1psycho1c)</p><p>Not considered or not specified 20</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Time interval</head><p>Not considered or not specified <ref type="bibr">20</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose</head><p>Not considered or not specified <ref type="bibr">20</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis</head><p>Clinical diagnosis of treatment-resistant SCZ and exclusion of patients with Parkinson Disease or oB-license indications (e.g. patients with alternative clinician diagnoses of bipolar aBective disorder and personality disorders) 20 Ultratreatment resistance Readmission following an inpatient episode where patient was discharged on clozapine Duration (of clozapine use)</p><p>Clozapine prescribed during an inpatient episode and then prescribed again at some point within the six weeks after discharge <ref type="bibr" target="#b139">21</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Time interval</head><p>Until first readmission, date of death, or the end of the observation period, whichever occurred first <ref type="bibr" target="#b139">21</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose</head><p>Not considered or not specified 21 Diagnosis SCZ or schizoaBective disorder (ICD-10 codes F20, F25) 21 Other criteria Ensure mortality was not mistaken as a lack of readmission by linking to national mortality database <ref type="bibr" target="#b139">21</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relapse</head><p>Hospitalization Duration (per antipsychotic)</p><p>Not considered or not specified <ref type="bibr">22,</ref><ref type="bibr">23</ref> ≥2 pharmacy claims for an oral antipsychotic since diagnosis and ≥1 antipsychotic monotherapy period of ≥90 days with a stable dose (up to 10% variation of the mean dose was allowed) <ref type="bibr" target="#b142">24</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Time interval</head><p>1-year period after first record of a diagnosis of psychotic disorder <ref type="bibr">22</ref> 6-months to 3-years period after first recorded diagnosis <ref type="bibr">23</ref> 2-year period <ref type="bibr" target="#b142">24</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose</head><p>Not considered or not specified </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose</head><p>Not considered or not specified <ref type="bibr">26</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnosis</head><p>Diagnosis of bipolar disorder type 1, type 2, not otherwise specified, or schizoaffec1ve disorder bipolar type according to the DSM-IV-TR) <ref type="bibr">26</ref> MDD = major depressive disorder; SCZ = schizophrenia; BIP = bipolar disorder; ICD = International Classification of Diseases; ECT = electroconvulsive therapy. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964874 (REALMENT), and from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057454 (Psych-STRATA). We also acknowledge support from the Research Council of Norway (296030, 300309, 324499, 334920), Nordforsk (164218), and Wellcome Trust (226770/Z/22/Z). This work was further supported by the MRC programme (MR/Y004094/1), MRC project Brain &amp; Genomics Hub of the Mental Health Platform (MR/Z503745/1), Svenska Sällskapet för Medicinsk Forskning (PD20-0190), Genomic Medicine Sweden (GMS K131050263), the Söderström König Foundation, University of Tartu grant (PLTGI24925), the US NIH (5R01MH124839-02, R01MH123724), the Swedish Research Council (2022-01643, 2021-02732, 2021-02615), Hjärnfonden/the Swedish Brain foundation (FO2022-0217), the Swedish Government under the LUA/ALF agreement (ALFGBG-965444, ALFGBG-966370), the European Research Council (101042183 and NIHR Maudsley Biomedical Research Centre. Declaration of interests Dr. Andreassen has received speaker fees from Lundbeck, Janssen, Otsuka, and Sunovion and is a consultant to Cortechs.ai. and Precision Health. Dr. Lewis sits on the Scientific Advisory Board for Myriad Neuroscience. Dr. Serretti has served as a consultant or speaker for Abbott, Abbvie, Angelini, AstraZeneca, Clinical Data, Boehringer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, and Servier and Taliaz. Dr. Molden has received speaker's honoraria from Lundbeck and Otsuka. Dr. Dawson is the owner of P1vital LTD. Dr. Einarsson, Dr. K. Stefánsson, and Dr. H. Stefánsson are employed at deCODE genetics, subsidiary of Amgen.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>MDD = major depressiveBox 1 :</head><label>1</label><figDesc>disorder; TRD = treatment-resistant depression; BIP = bipolar disorder; ICD = International Classification of Diseases; ECT = electroconvulsive therapy; TMS = transcranial magnetic stimulation. ATC = anatomical therapeutic chemical. TDM = therapeutic drug monitoring. Recommendations for antidepressant treatment outcome definitions in major depressive disorder Non-response/treatment-resistant depression: • Diagnosis of major depression and • Antidepressant switching (≥2 antidepressant trials of adequate dose and duration) and/or • Hospitalization during treatment and/or • Neurostimulation (electroconvulsive therapy or transcranial magnetic stimulation) and/or • Treatment with (es)ketamine and/or • Self-reported non-response after ≥2 antidepressant trials and • Treatment adherence Remission/response: • Diagnosis of major depression and • History of stable treatment and • No history of neurostimulation (electroconvulsive therapy or transcranial magnetic stimulation) and • No history of treatment with (es)ketamine and • No hospitalization during treatment and/or • Self-reported treatment response and • Treatment adherence</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>MDD = major depressive</head><label></label><figDesc>disorder; SCZ = schizophrenia; BIP = bipolar disorder; ICD = International Classification of Diseases; ATC = anatomical therapeutic chemical; ECT = Electroconvulsive therapy. TDM = therapeutic drug monitoring.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc>BIP = bipolar disorder; ICD = International Classification of Diseases; ATC = anatomical therapeutic chemical; ECT = Electroconvulsive therapy; TMS = transcranial magnetic stimulation. TDM = therapeutic drug monitoring.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 :</head><label>1</label><figDesc>Recommendations for measuring treatment outcomes in major depression using real-world data</figDesc><table><row><cell>RWD sources</cell><cell>Phenotype</cell><cell>Criteria</cell></row><row><cell>Popula8on-wide</cell><cell></cell><cell></cell></row><row><cell>health registries</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 :</head><label>2</label><figDesc>Recommendations for measuring treatment outcomes in schizophrenia using real-world data</figDesc><table><row><cell>RWD sources</cell><cell>Phenotype</cell><cell>Criteria</cell></row><row><cell>Popula8on-wide</cell><cell></cell><cell></cell></row><row><cell>health registries</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Box 2 :</head><label>2</label><figDesc>Recommendations for antipsychotic treatment outcome definitions in schizophrenia</figDesc><table><row><cell>Treatment-resistant schizophrenia:</cell></row><row><cell>• Diagnosis of schizophrenia and</cell></row><row><cell>• Lifetime clozapine use and/or</cell></row><row><cell>• Antipsychotic switching (≥2 antipsychotic trials of adequate dose and duration) and/or</cell></row><row><cell>• Electroconvulsive therapy and/or</cell></row><row><cell>• Hospitalization during treatment and/or</cell></row><row><cell>• Self-reported non-response after ≥2 antipsychotic trials and</cell></row><row><cell>• Treatment adherence</cell></row><row><cell>Non-resistance/Response:</cell></row><row><cell>• Diagnosis of schizophrenia and</cell></row><row><cell>• No history of clozapine and</cell></row><row><cell>• No history of electroconvulsive therapy and</cell></row><row><cell>• History of stable treatment and</cell></row><row><cell>• No hospitalization during treatment and/or</cell></row><row><cell>• Self-reported treatment response and</cell></row><row><cell>• Treatment adherence</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 :</head><label>3</label><figDesc>Recommendations for measuring treatment outcomes in bipolar disorder using RWD</figDesc><table><row><cell>RWD sources</cell><cell>Phenotype</cell><cell>Criteria</cell></row><row><cell>Popula8on-wide</cell><cell></cell><cell></cell></row><row><cell>health registries</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Box 3 :Table 1 :</head><label>31</label><figDesc>Recommendations for treatment outcome definitions in bipolar disorderNon-response/treatment-resistance:• Diagnosis of bipolar disorder and • Medication switching (≥2 trials of medications (different criteria for non-response/resistance during maintenance treatment, mania, or bipolar depression), of adequate dose and duration) and/or • Hospitalization during treatment (maintenance, mania, or depression) and/or Proxy measures of psychotropic treatment outcomes using real-world data in the literature.</figDesc><table><row><cell cols="2">Supplementary Measure Defini,on</cell><cell>Criteria</cell><cell></cell></row><row><cell cols="3">An,depressant treatment outcome measures</cell><cell></cell></row><row><cell>Treatment</cell><cell>≥2 switches between</cell><cell>Dura1on (per</cell><cell>6-14 weeks 1</cell></row><row><cell cols="4">• Neurostimulation (electroconvulsive therapy or transcranial magnetic stimulation) during treatment resistance an1depressant drugs drug) At least 6 weeks 2</cell></row><row><cell cols="3">(maintenance, mania, or depression) and/or prescribed for an</cell><cell>30 days-14 weeks 3</cell></row><row><cell cols="3">• Treatment with (es)ketamine and/or adequate dura1on in</cell><cell></cell></row><row><cell cols="2">• Clozapine treatment and/or individuals diagnosed</cell><cell></cell><cell></cell></row><row><cell cols="4">• Polypharmacy (combined treatment with ≥3 medications for maintenance treatment, treatment of with a depressive</cell></row><row><cell cols="4">mania, or treatment of bipolar depression) and/or disorder</cell></row><row><cell cols="4">• Self-reported non-response after ≥2 trials of medications (for maintenance treatment, treatment of</cell></row><row><cell cols="4">mania, or treatment of bipolar depression) and</cell></row><row><cell cols="2">• Treatment adherence</cell><cell></cell><cell></cell></row><row><cell cols="2">Non-resistance/response:</cell><cell></cell><cell></cell></row><row><cell cols="3">• Diagnosis of bipolar disorder and</cell><cell></cell></row><row><cell cols="3">• History of stable treatment and</cell><cell></cell></row><row><cell cols="2">• No history of clozapine and</cell><cell></cell><cell></cell></row><row><cell cols="4">• No history of neurostimulation (electroconvulsive therapy or transcranial magnetic stimulation)</cell></row><row><cell cols="3">during mood stabilizer treatment and</cell><cell></cell></row><row><cell cols="3">• No hospitalization during treatment and/or</cell><cell></cell></row><row><cell cols="3">• Self-reported treatment response and</cell><cell></cell></row><row><cell cols="2">• Treatment adherence</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head></head><label></label><figDesc>22-24 Diagnosis Patients with psychotic disorders, including SCZ spectrum disorders, mood disorders with psychotic symptoms, and other psychotic disorders 22 SCZ or schizoaBective disorder (ICD-10 codes F20, F25) 23 ≥1 diagnosis of SCZ, BIP, or MDD 24 Other criteria &gt;365 days of health records coverage and history of antipsychotics medication (≥2 records of antipsychotic exposure after first diagnosis) or a history of psychiatric procedure (≥2 records of psychotherapy or ECT after first diagnosis) 22 ≥2 records at least 12 months apart 23 ≥6 months of continuous enrollment prior to first prescription date for the new antipsychotic 24</figDesc><table><row><cell cols="3">Mood stabilizer treatment outcome measures</cell><cell></cell></row><row><cell>Lithium</cell><cell>Lithium monotherapy</cell><cell>Dura1on of</cell><cell>≥6 months 25</cell></row><row><cell>response</cell><cell>(no an1depressants,</cell><cell>lithium</cell><cell></cell></row><row><cell></cell><cell>an1psycho1cs, or</cell><cell>treatment</cell><cell></cell></row><row><cell></cell><cell>an1epilep1cs) and no</cell><cell>Dose</cell><cell>Not considered or not specified 25</cell></row><row><cell></cell><cell>hospitaliza1on</cell><cell>Diagnosis:</cell><cell>ICD-10 index diagnosis of mania or BIP (ICD-10 code:</cell></row><row><cell></cell><cell></cell><cell></cell><cell>DF30-31.9) and no SCZ diagnosis 25</cell></row><row><cell></cell><cell>Defini1on based on</cell><cell>Dura1on of</cell><cell>≥12 months 26</cell></row><row><cell></cell><cell>self-reports</cell><cell>lithium</cell><cell></cell></row><row><cell></cell><cell></cell><cell>treatment</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 2 :</head><label>2</label><figDesc>Recommendations for measuring psychopharmacological treatment outcomes using free text from electronic health records Measure Criteria Hospitaliza1on Hospitaliza1on due to MDD/BIP/SCZ derived from hospital records Long-term care Can be derived from physician notes Level of functioning Can be derived from patient-reported outcome measures (PROMS), for example information about employment, or days of sick-leave Remission Can be derived from clinical symptom scores Treatment adherence Derived from physician notes. Non-adherence should be excluded. Symptoms From specialist health care or primary health care as well as from PROMS</figDesc><table /><note></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Appendix</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Content</head> <ref type="figure">Supplementary Figure 1</ref> <p>1 <ref type="table">Supplementary Table 1  2  Supplementary Table 2</ref> 4 References</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Jauhar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Johnstone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">J</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Schizophrenia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<biblScope unit="volume">399</biblScope>
			<biblScope unit="page" from="473" to="486" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Mcintyre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Berk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Brietzke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">I</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>López-Jaramillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">V</forename><surname>Kessing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bipolar disorders. The Lancet</title>
		<imprint>
			<biblScope unit="volume">396</biblScope>
			<biblScope unit="page" from="1841" to="1856" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Malhi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Mann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Depression. The Lancet</title>
		<imprint>
			<biblScope unit="volume">392</biblScope>
			<biblScope unit="page" from="2299" to="2312" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">N</forename><surname>Fountoulakis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">N</forename><surname>Yatham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Grunze</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Vieta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Blier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="230" to="256" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Huhn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Tardy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Spineli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Kissling</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Förstl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Pitschel-Walz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="706" to="715" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Treatment resistance in psychiatry: state of the art and new directions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">D</forename><surname>Howes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Thase</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Pillinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="58" to="72" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Siskind</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Siskind</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kisely</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="772" to="777" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The Role of Clozapine in Treatment-Resistant Schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="187" to="188" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Treatment-resistant bipolar disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Gitlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="227" to="240" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Mcintyre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Alsuwaidan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">T</forename><surname>Baune</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Berk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Demyttenaere</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="394" to="412" />
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Treatmentresistant and multi-therapy-resistant criteria for bipolar depression: consensus definition</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hidalgo-Mazzei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Berk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Cipriani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Cleare</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">D</forename><surname>Florio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Dietch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">214</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="27" to="35" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Burden of illness in bipolar depression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Manning</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prim Care Companion J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="259" to="267" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Ascher-Svanum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Faries</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">R</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Swartz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Swanson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="453" to="460" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Novick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Haro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Suarez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">W</forename><surname>Dittmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">M</forename><surname>Haddad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatry Res</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="issue">2-3</biblScope>
			<biblScope unit="page" from="109" to="113" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Cipriani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">A</forename><surname>Furukawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Salanti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Chaimani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">Z</forename><surname>Atkinson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Ogawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Focus (Am Psychiatr Publ</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="420" to="429" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Novel and emerging treatments for major depression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Marwaha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Suppes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Cons</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Upthegrove</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">401</biblScope>
			<biblScope unit="page" from="141" to="153" />
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">History, background, concepts and current use of comedication and polypharmacy in psychiatry</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Möller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Seemüller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Schennach-Wolff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Stübner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Rüther</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Grohmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The International Journal of Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">07</biblScope>
			<biblScope unit="page" from="983" to="996" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wolff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Hefner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Normann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kaier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Binder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Hiemke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacoepidemiology and Drug Safety</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1258" to="1268" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The limitations of using randomised controlled trials as a basis for developing treatment guidelines</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Mulder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">B</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Outhred</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Morris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Evid Based Ment Health</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="4" to="6" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Takeuchi</surname></persName>
		</author>
		<idno>113098. 21</idno>
		<ptr target="https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence.Accessed27" />
	</analytic>
	<monogr>
		<title level="j">Behav Brain Res</title>
		<imprint>
			<biblScope unit="volume">402</biblScope>
			<date type="published" when="2021" />
		</imprint>
	</monogr>
	<note>US Food and Drug Administration. Real-World Evidence</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Cave</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Kurz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Arlett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="36" to="39" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Arlett</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kjaer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Broich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Cooke</surname></persName>
		</author>
		<ptr target="https://www.ema.europa.eu/en/documents/report/european-union-medicines-agencies-network-strategy-2025-protecting-public-health-time-rapid-change_en.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="21" to="23" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>European medicines agencies network strategy to 2025</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Wettermark</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Zoega</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Furu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Korhonen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Hallas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Norgaard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacoepidemiol Drug Saf</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="691" to="699" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">How realworld data can facilitate the development of precision medicine treatment in psychiatry</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">F</forename><surname>Pardiñas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Connell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">S</forename><surname>Selvaggi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Collados</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Babic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biological Psychiatry</title>
		<imprint>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">P</forename><surname>Hagenaars</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>John</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">T</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Shrine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Moles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="3363" to="3373" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Genomewide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">M</forename><surname>Wigmore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Hafferty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">S</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">K</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Fabbri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics J</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="329" to="341" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">Phenotype-by-phenome-wide association study of treatment resistant depression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">J</forename><surname>Coombes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Sanchez Ruiz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Fennessy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Pazdernik</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Adekkanattu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">A</forename><surname>Nunez</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Efficiently identifying individuals at high risk for treatment resistance in major depressive disorder using electronic health records</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Lage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">H</forename><surname>Mccoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jr</forename><surname>Perlis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Doshi-Velez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Affect Disord</title>
		<imprint>
			<biblScope unit="volume">306</biblScope>
			<biblScope unit="page" from="254" to="259" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Kubitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mehra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">C</forename><surname>Potluri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Cossrow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">76882</biblScope>
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Susceptibility to Treatment-Resistant Depression Within Families</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">F</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="663" to="672" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pappa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Anwar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ming</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJPsych Open</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">32</biblScope>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Döme</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Kunovszki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Takacs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Feher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Balazs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dede</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">245510</biblScope>
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Fife</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Sheehan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Boden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Brandt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">23</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Cars</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Loov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Soderling</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Sundstrom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Tiihonen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="167" to="175" />
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Healthcare resource utilization in patients with treatment-resistant depression-A Danish national registry study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">J</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">H</forename><surname>Gronemann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Z</forename><surname>Ankarfeldt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Jimenez-Solem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Alulis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Riise</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">275299</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Polygenic risk scores of lithium response and treatment resistance in major depressive disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kowalec</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Ruck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Sigstrom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl Psychiatry</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">301</biblScope>
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Genome-Wide Association Study of Treatment-Resistant Depression: Shared Biology With Metabolic Traits</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">M</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ripperger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Venkatesh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Burstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">K</forename><surname>Linner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="608" to="619" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Assessment of a Prediction Model for Antidepressant Treatment Stability Using Supervised Topic Models</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Pradier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">S</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">H</forename><surname>Mccoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jr</forename><surname>Perlis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Doshi-Velez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">205308</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wle</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Laplace</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Van Westrhenen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Lewis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmaceuticals (Basel)</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">9</biblScope>
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">AI-assisted prediction of differential response to antidepressant classes using electronic health records</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Sheu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Magdamo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Blacker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Smoller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">NPJ Digit Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">73</biblScope>
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Perlis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">V</forename><surname>Iosifescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">M</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">N</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">S</forename><surname>Gainer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Minnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychol Med</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="41" to="50" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Genome-wide association studies of antidepressant class response and treatment-resistant depression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><forename type="middle">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hinds</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Research</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl Psychiatry</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">360</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Phenotypic analysis of 23andMe survey data: Treatment-resistant depression from participants&apos; perspective</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><forename type="middle">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Mcintyre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Research</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">A</forename><surname>Hinds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatry Res</title>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="page" from="173" to="179" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Jürgenson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Einarsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Harder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Garcia-Marin</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">Genome-wide meta-analyses of non-response to antidepressants identify novel loci and potential drugs</title>
		<imprint>
			<biblScope unit="volume">2024</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Exploring the incidence of inadequate response to antidepressants in the primary care of depression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">B</forename><surname>Abrahams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">C</forename><surname>Beckenstrom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Browning</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Dias</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">M</forename><surname>Goodwin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Gorwood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="61" to="70" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Quality of Life and Functioning in Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder After Treatment With Citalopram Monotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Steiner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Boulos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Mirocha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Collison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">W</forename><surname>Ishak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Neuropharmacol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="16" to="23" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Perlman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Benrimoh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Israel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Rollins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Tunteng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Affect Disord</title>
		<imprint>
			<biblScope unit="volume">243</biblScope>
			<biblScope unit="page" from="503" to="515" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Socio-demographic and clinical predictors of nonresponse/non-remission in treatment resistant depressed patients: A systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>De Carlo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Calati</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Serretti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatry Res</title>
		<imprint>
			<biblScope unit="volume">240</biblScope>
			<biblScope unit="page" from="421" to="430" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">D</forename><surname>Howes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Mccutcheon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Agid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>De Bartolomeis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">J</forename><surname>Van Beveren</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Birnbaum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="216" to="229" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">A predictor model of treatment resistance in schizophrenia using data from electronic health records</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kadra-Scalzo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Fonseca De Freitas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Agbedjro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Ridler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pritchard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">274864</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Increased schizophrenia family history burden and reduced premorbid IQ in treatmentresistant schizophrenia: a Swedish National Register and Genomic Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kowalec</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Sariaslan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ploner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Dalman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="4487" to="4495" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Predictors of longterm (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kadra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Shetty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Downs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Maccabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="issue">1-3</biblScope>
			<biblScope unit="page" from="106" to="112" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Kyllesø</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ø</forename><surname>Karlstad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">A</forename><surname>Andreassen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Molden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">NPJ Schizophr</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">17</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Lenk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">S</forename><surname>O'connell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">A</forename><surname>Andreassen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Molden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS Drugs</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="473" to="480" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Gasse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Wimberley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Mors</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Borglum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">D</forename><surname>Als</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="page" from="79" to="85" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Wimberley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Gasse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Agerbo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Maccabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">T</forename><surname>Horsdal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia bulletin</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1064" to="1069" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">F</forename><surname>Pardiñas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Holmans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Pocklington</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Escott-Price</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ripke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Carrera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="381" to="389" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">F</forename><surname>Pardinas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Smart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">R</forename><surname>Willcocks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Holmans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Dennison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Lynham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="260" to="269" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Taipale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Puranen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Mittendorfer-Rutz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Tiihonen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Tanskanen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Cervenka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nord J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="315" to="322" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wellesley</forename><surname>Wesley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Kadra-Scalzo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Shetty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Broadbent</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">232</biblScope>
			<biblScope unit="page" from="68" to="76" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">F</forename><surname>De Freitas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kadra-Scalzo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Shetty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Broadbent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Soc Psychiatry Psychiatr Epidemiol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1341" to="1355" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Molden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Drug Metab Toxicol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1211" to="1221" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kesserwani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kadra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Downs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Shetty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Maccabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="449" to="458" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Psychosis Relapse Prediction Leveraging Electronic Health Records Data and Natural Language Processing Enrichment Methods</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Son</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Psychiatry</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">844442</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Real-world predictors of relapse in patients with schizophrenia and schizoaffective disorder in a large health system</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rivelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Fitzpatrick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Laubmeier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Zeni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Mylavarapu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia (Heidelb)</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">28</biblScope>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Ayyagari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Thomason</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Philbin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Carroll</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="204" to="212" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Is response to prophylactic lithium a familial trait?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Grof</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Cavazzoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Grof</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Garnham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Macdougall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>'donovan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="942" to="947" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Tohen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Frank</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Bowden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Colom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">N</forename><surname>Ghaemi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">N</forename><surname>Yatham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bipolar Disord</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="453" to="473" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Predictors of excellent response to lithium: results from a nationwide register-based study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">V</forename><surname>Kessing</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Hellmund</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">K</forename><surname>Andersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="323" to="328" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Genomewide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Bergen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Di</forename><surname>Florio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Charney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ruderfer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1290" to="1297" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Factors associated with self-perceived treatment-resistance in bipolar disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Fujimura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Taira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yamasuji</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Shimizu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine (Baltimore)</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">36217</biblScope>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Genetic contribution to disease-course severity and progression in the SUPER-Finland study, a cohort of 10,403 individuals with psychotic disorders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Kämpe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Suvisaari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lähteenvuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ahola-Olli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Urpa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2733" to="2741" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Prospective cohort study of early biosignatures of response to lithium in bipolar-Idisorders: overview of the H2020-funded R-LiNK initiative</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hidalgo-Mazzei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Strawbridge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Resche-Rigon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Etain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Bipolar Disord</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Marston</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Walters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Geddes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dpj</forename><surname>Osborn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="53" to="58" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Treatment-resistant bipolar depression: towards a new definition</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Pacchiarotti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Mazzarini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Colom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Sanchez-Moreno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Girardi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">D</forename><surname>Kotzalidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="429" to="440" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Association of Occupational Dysfunction and Hospital Admissions With Different Polygenic Profiles in Bipolar Disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Jonsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Hörbeck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Primerano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Smedler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="620" to="629" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Randomised controlled trials -the gold standard for effectiveness research: Study design: randomised controlled trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Hariton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Locascio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bjog</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page">1716</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Zimmerman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">I</forename><surname>Mattia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Posternak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="469" to="473" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Efficacy-Effectiveness Gap&quot;: Historical Background and Current Conceptualization</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Nordon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Karcher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Groenwold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Z</forename><surname>Ankarfeldt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Pichler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Chevrou-Severac</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Value Health</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="75" to="81" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Allemann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Nieuwlaat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Navarro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Haynes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">E</forename><surname>Hersberger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Arnet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="70" to="79" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Taliaz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Serretti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS Neurol Disord Drug Targets</title>
		<imprint>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">N</forename><surname>Fountoulakis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Saitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">F</forename><surname>Schatzberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">2025</biblScope>
			<biblScope unit="page">20240515</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lima</forename><surname>Constantino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Godschalk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Van Dalfsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Veraart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jke</forename><surname>Spijker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Van Exel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatry Res</title>
		<imprint>
			<biblScope unit="volume">345</biblScope>
			<biblScope unit="page">116355</biblScope>
			<date type="published" when="2025" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Roadmap for a precision-medicine initiative in the Nordic region</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Njolstad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">A</forename><surname>Andreassen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Brunak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">D</forename><surname>Borglum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Dillner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Esko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="924" to="930" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian Biobank</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Alver</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kasela</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Haring</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">B</forename><surname>Luitva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Estonian</forename><surname>Biobank Research</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Health Informatics Research</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Reg Health Eur</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page">100914</biblScope>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">The quality of severe mental disorder diagnoses in a national health registry as compared to research diagnoses based on structured interview</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Nesvåg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">G</forename><surname>Jönsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">J</forename><surname>Bakken</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">P</forename><surname>Knudsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">D</forename><surname>Bjella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Reichborn-Kjennerud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Psychiatry</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">93</biblScope>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Scientific validation of the ICD-11 CDDR</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Maj</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="358" to="359" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Antidepressants for insomnia in adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Everitt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Baldwin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lipinska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Mayers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">L</forename><surname>Malizia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">10753</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Antipsychotics for agitation and psychosis in people with Alzheimer&apos;s disease and vascular dementia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Mühlbauer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Möhler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">N</forename><surname>Dichter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">U</forename><surname>Zuidema</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Köpke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Luijendijk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">13304</biblScope>
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Natural language processing systems for capturing and standardizing unstructured clinical information: A systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kreimeyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Arya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Halford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">F</forename><surname>Jones</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biomed Inform</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="14" to="29" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Polygenic liability for antipsychotic dosage and polypharmacy -a real-world registry and biobank study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Kämpe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Alver</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Sigurðarson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Einarsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Partanen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1113" to="1119" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">E</forename><surname>Lévesque</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Hanley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Kezouh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Suissa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bmj</title>
		<imprint>
			<biblScope unit="volume">340</biblScope>
			<biblScope unit="page">5087</biblScope>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Immortal Time Bias in Observational Studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yadav</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Lewis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jama</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="686" to="687" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">A Delphimethod-based consensus guideline for definition of treatment-resistant depression for clinical trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Sforzini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Worrell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kose</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">M</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Aouizerate</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Arolt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1286" to="1299" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<monogr>
		<title level="m" type="main">Guideline on clinical investigation of medicinal products in the treatment of depression. EMA/CHMP/185423</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Agency</forename><surname>European Medicines</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">A register-based approach to identifying treatment-resistant depression-Comparison with clinical definitions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hagg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Reutfors</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Dibernardo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Boden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">236434</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expertbased heuristics</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Cepeda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Reps</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Fife</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Blacketer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Stang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Ryan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Depress Anxiety</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="220" to="228" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Cohort Profile: Estonian Biobank of the Estonian Genome Center</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Leitsalu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Haller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Esko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Tammesoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Alavere</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Snieder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1137" to="1147" />
			<date type="published" when="2015" />
		</imprint>
		<respStmt>
			<orgName>University of Tartu</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Cohort Profile Update: Mental Health Online Survey in the Estonian Biobank (EstBB MHoS)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ojalo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Haan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Koiv</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">M</forename><surname>Kariis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Krebs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Uusberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Cohort profile: SUPER-Finland -the Finnish study for hereditary mechanisms of psychotic disorders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lähteenvuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ahola-Olli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Suokas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Holm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Misiewicz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Jukuri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">70710</biblScope>
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<monogr>
		<title level="m" type="main">Cross-EHR validation of antidepressant response algorithm and links with genetics of psychiatric traits</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Sealock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Tubbs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Lake</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Straub</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Smoller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">K</forename><surname>Davis</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">2024</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Sudlow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Gallacher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Beral</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Burton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Danesh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">1001779</biblScope>
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">The All of Us Research Program: Data quality, utility, and diversity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">H</forename><surname>Ramirez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Sulieman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Schlueter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Halvorson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Ratsimbazafy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Patterns (N Y)</title>
		<imprint>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">The Evolving Uses of &quot;Real-World&quot; Data</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Basch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Schrag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jama</title>
		<imprint>
			<biblScope unit="volume">321</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1359" to="1360" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Contribution of Real-World Evidence in European Medicines Agency&apos;s Regulatory Decision Making</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Bakker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Plueschke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Jonker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Kurz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Starokozhko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pgm</forename><surname>Mol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="135" to="151" />
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Realworld evidence for regulatory decision-making: updated guidance from around the world</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Burns</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Le</forename><surname>Roux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Kalesnik-Orszulak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Christian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Dudinak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Rockhold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Med (Lausanne)</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">1236462</biblScope>
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Alipour-Haris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Acha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">G</forename><surname>Winterstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Burcu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Sci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">13903</biblScope>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Medication for attention deficit-hyperactivity disorder and criminality</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Lichtenstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Halldner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zetterqvist</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Sjolander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Serlachius</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Fazel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="2006" to="2014" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Viktorin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Lichtenstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Thase</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Larsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Lundholm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">K</forename><surname>Magnusson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1067" to="1073" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">The promise and challenges of drug repurposing in psychiatry</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Fava</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="28" to="29" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Candidates for drug repurposing to address the cognitive symptoms in schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kauppi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog Neuropsychopharmacol Biol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page">110637</biblScope>
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Drug repurposing candidates to treat core symptoms in autism spectrum disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Demontis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Pharmacol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">995439</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">R</forename><surname>Reay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">P</forename><surname>Geaghan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">J</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Cairns</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American journal of human genetics</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1620" to="1637" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<monogr>
		<title level="m" type="main">Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and Compounds</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Shadrin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Fuhrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gfl</forename><surname>Hindley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Stinson</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">2024</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lundin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Wicks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ick</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dpj</forename><surname>Osborn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="382" to="390" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">A Normative Framework for the Reconciliation of EU Data Protection Law and Medical Research Ethics</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hallinan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Law Rev</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="446" to="467" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<monogr>
		<title level="m" type="main">Supplementary Figure 1: Using large-scale real-world data to define and validate pharmacological treatment outcomes. RWD = real-world data, eHRs = electronic health records References</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">P</forename><surname>Hagenaars</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>John</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">T</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Shrine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Moles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="3363" to="3373" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">M</forename><surname>Wigmore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Hazerty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">S</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">K</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Fabbri</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and metaanalysis with GENDEP</title>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics J</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="329" to="341" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<monogr>
		<title level="m" type="main">Phenotype-by-phenome-wide association study of treatment resistant depression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">J</forename><surname>Coombes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Sanchez Ruiz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Fennessy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Pazdernik</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Adekkanattu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">A</forename><surname>Nunez</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">EZiciently identifying individuals at high risk for treatment resistance in major depressive disorder using electronic health records</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Lage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">H</forename><surname>Mccoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jr</forename><surname>Perlis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Doshi-Velez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J A9ect Disord</title>
		<imprint>
			<biblScope unit="volume">306</biblScope>
			<biblScope unit="page" from="254" to="259" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Kubitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mehra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">C</forename><surname>Potluri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Cossrow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">76882</biblScope>
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Susceptibility to Treatment-Resistant Depression Within Families</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">F</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="663" to="672" />
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pappa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Anwar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ming</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJPsych Open</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">32</biblScope>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Clinical characteristics of treatment-resistant depression in adults in Hungary: Realworld evidence from a 7-year-long retrospective data analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Döme</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Kunovszki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Takacs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Feher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Balazs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dede</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">245510</biblScope>
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Fife</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Sheehan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Boden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Brandt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">23</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Cars</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Loov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Soderling</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Sundstrom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Tiihonen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="167" to="175" />
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Healthcare resource utilization in patients with treatment-resistant depression-A Danish national registry study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">J</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">H</forename><surname>Gronemann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Z</forename><surname>Ankarfeldt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Jimenez-Solem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Alulis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Riise</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">275299</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Polygenic risk scores of lithium response and treatment resistance in major depressive disorder</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kowalec</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Ruck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Sigstrom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl Psychiatry</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">301</biblScope>
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Perlis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">V</forename><surname>Iosifescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">M</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">N</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">S</forename><surname>Gainer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Minnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychol Med</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="41" to="50" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Assessment of a Prediction Model for Antidepressant Treatment Stability Using Supervised Topic Models</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">F</forename><surname>Pradier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">S</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">H</forename><surname>Mccoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jr</forename><surname>Perlis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Doshi-Velez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">205308</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Genome-wide association studies of antidepressant class response and treatment-resistant depression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><forename type="middle">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hinds</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Research</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl Psychiatry</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">360</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Gasse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Wimberley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Mors</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Borglum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">D</forename><surname>Als</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="page" from="79" to="85" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Wimberley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Gasse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Agerbo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Maccabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">T</forename><surname>Horsdal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia bulletin</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1064" to="1069" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">A predictor model of treatment resistance in schizophrenia using data from electronic health records</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kadra-Scalzo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Fonseca De Freitas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Agbedjro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Ridler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pritchard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">274864</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Increased schizophrenia family history burden and reduced premorbid IQ in treatmentresistant schizophrenia: a Swedish National Register and Genomic Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kowalec</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Sariaslan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ploner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Dalman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="4487" to="4495" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">F</forename><surname>Pardiñas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Holmans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Pocklington</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Escott-Price</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ripke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Carrera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="381" to="389" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Risk of readmission in patients with schizophrenia and schizoaZective disorder newly prescribed clozapine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kesserwani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kadra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Downs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Shetty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Maccabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="449" to="458" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Psychosis Relapse Prediction Leveraging Electronic Health Records Data and Natural Language Processing Enrichment Methods</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Son</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Psychiatry</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">844442</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Real-world predictors of relapse in patients with schizophrenia and schizoaZective disorder in a large health system</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rivelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Fitzpatrick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Laubmeier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Zeni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Mylavarapu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia (Heidelb)</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">28</biblScope>
			<date type="published" when="2024" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Ayyagari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Thomason</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Philbin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Carroll</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="204" to="212" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Predictors of excellent response to lithium: results from a nationwide register-based study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">V</forename><surname>Kessing</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Hellmund</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">K</forename><surname>Andersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="323" to="328" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Bergen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Di</forename><surname>Florio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Charney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ruderfer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder</title>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1290" to="1297" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
